Drug Profile


Alternative Names: Agilect; AGN 1135; Azilect; Elbrus; Lu 00-773; Rasagiline mesilate; Rasagiline mesylate; TV-1030; TVP 101; TVP 1012

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Lundbeck A/S; Takeda; Teva Pharmaceutical Industries
  • Class Antiparkinsonians; Indans; Small molecules
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Jun 2017 Preregistration for Parkinson's disease in Japan (PO)
  • 16 Mar 2017 Takeda completes a long-term extension phase III trial for Parkinson's disease (Early-stage disease) in Japan (NCT02337751)
  • 01 Sep 2016 Takeda completes a phase III trial for Parkinson's disease in Japan (NCT02337764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top